Institute News
Most Popular
What To Expect in a MacTel Imaging Exam
April 29, 2024 The following information was sent out via email to people who registered in the LMRI Contact Database. This post will explain some (but not all) of the imaging exams that your eye doctor may perform during a screeni...
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macul...
Phase 3 Trial Currently Enrolling MacTel Patients
Neurotech Pharmaceuticals, with support from the Lowy Medical Research Institute, is currently enrolling a Phase 3 clinical trial testing ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia type 2. This is a multi-center trial...
CNTF Clinical Trials: COVID-19 Update
March 24, 2020 The rapid spread of COVID-19 has disrupted many standard clinical operations, including the LMRI/Neurotech Phase 1, 2, and 3 clinical trials testing CNTF in MacTel. If you have questions regarding upcoming appointments or other study-...
Neurotech Receives Priority Review of Biologics License Application for NT-501 as a Treatment for Macular Telangiectasia Type 2
June 20, 2024 LMRI would like to share the news that Neurotech has received Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a treatment for MacTel. For more information, please refer to the Neurotech...
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)
LMRI would like to share the following press release from Neurotech Pharmaceuticals about the BLA for NT-501 as a treatement for MacTel: Cumberland, R.I., November 8, 2024 (BUSINESS WIRE) – Neurotech Pharmaceuticals, Inc., an innovator in sustained...